Tonix Pharmaceuticals: Additional Data Reassuring
Edison | Nov 24, 2015 11:34PM ET
Tonix Pharmaceuticals (O:TNXP)
Additional data support mechanism of action
Data from the Phase IIb BESTFIT trial reported at the American College of Rheumatology (ACR) conference support the idea that improvements in sleep quality are correlated with improvements in pain. As Tonmya (TNX- 102 SL) benefits sleep quality, these data are reassuring and we continue to be confident in the success of the Phase III AFFIRM trial. Data from the AFFIRM trial are expected in Q316.
ACR data suggest correlation between sleep and pain
Data from the BESTFIT trial in fibromyalgia presented at ACR on 10 November demonstrated that improvements in sleep quality were associated with higher responder rates in pain and fibromyalgia. Of the patients who were in the top sleep score improvement tertile, 78% of those in the Tonmya arm were pain responders, compared to just 4% in the bottom sleep score improvement tertile.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.